The primary objective of the translational core is to provide patient access and quality data collection. In order to constuct clinical cohorts for translational investigations, we have chosen to use two populations enriched for pulmonary arterial hypertension - COPD and HIV. Both COPD and HIV+ patients develop pulmonary hypertension at a rate significantly greater than the general population. Morbidity and mortality are also greatly increased in dually affected persons. Through our ongoing clinical studies, we have access to well-charaterized research subjects who are at risk for pulmonary arterial hypertension (PAH). Available cohorts include an Emphysema Registry, Lung Tissue Research Consortium participante, smokers enrolled in our COPD Specialized Center of Clinically Oriented Research grant, and HIV-infected and HIV-uninfected controls from local and multicenter trials. Together, these populations comprise over 2000 research subjects. The human core will support goals of all projects by identifying and characterizing populations to be used for evaluating mechanistic pathways in various PAH sub-phenotypes and by establishing clinical cohorts in whom to test novel therapeutic agents. The core will provide expertise in population screening, use of biomarkers, genomics, computed tomography, Doppler-echocardiography, and right heart catheterization in order to identify and characterize the subphenotypes of PAH in COPD and HIV. The core will supply imaging, catheterization, biobanking, and bioinformatics and statistical support for all Projects. Importantly, the clinical core will synergize with the pre-clinical core to translate findings from bench-to-bedside. The core will meet its goals by addressing the following Specific Aims:
Specific Aim 1 : To establish a cohort exhibiting the PAH phenotype from our diverse patient populations in order to support the Research Projects in translational investigations and to assess utility of plasma NT-proBNP as a biomarker of PAH.
Specific Aim 2 : To assist program investigators in testing novel therapeutic interventions in pulmonary arterial hypertension.
Specific Aim 3. To establish a biorepository for mechanistic studies of PAH sub-phenotypes.
Both COPD and HIV-infected patients are disproportionally affected by pulmonary arterial hypertension (PAH). Little work has been done to understand these particular phenotypes of PAH. Establishing a cohort in whom to explore mechanisms of disease pathogenesis and for testing of novel therapeutics would have a large public health impact for these populations and others who suffer from PAH.
|Raghu, Vineet K; Ramsey, Joseph D; Morris, Alison et al. (2018) Comparison of strategies for scalable causal discovery of latent variable models from mixed data. Int J Data Sci Anal 6:33-45|
|Kudryashova, Tatiana V; Shen, Yuanjun; Pena, Andressa et al. (2018) Inhibitory Antibodies against Activin A and TGF-? Reduce Self-Supported, but Not Soluble Factors-Induced Growth of Human Pulmonary Arterial Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension. Int J Mol Sci 19:|
|Freeman, Bruce A; O'Donnell, Valerie B; Schopfer, Francisco J (2018) The discovery of nitro-fatty acids as products of metabolic and inflammatory reactions and mediators of adaptive cell signaling. Nitric Oxide 77:106-111|
|Villacorta, Luis; Minarrieta, Lucia; Salvatore, Sonia R et al. (2018) In situ generation, metabolism and immunomodulatory signaling actions of nitro-conjugated linoleic acid in a murine model of inflammation. Redox Biol 15:522-531|
|Remy, Kenneth E; Cortés-Puch, Irene; Solomon, Steven B et al. (2018) Haptoglobin improves shock, lung injury, and survival in canine pneumonia. JCI Insight 3:|
|Rom, Oren; Khoo, Nicholas K H; Chen, Y Eugene et al. (2018) Inflammatory signaling and metabolic regulation by nitro-fatty acids. Nitric Oxide :|
|D'Amore, Antonio; Fazzari, Marco; Jiang, Hong-Bin et al. (2018) Nitro-Oleic Acid (NO2-OA) Release Enhances Regional Angiogenesis in a Rat Abdominal Wall Defect Model. Tissue Eng Part A 24:889-904|
|Schopfer, Francisco J; Vitturi, Dario A; Jorkasky, Diane K et al. (2018) Nitro-fatty acids: New drug candidates for chronic inflammatory and fibrotic diseases. Nitric Oxide 79:31-37|
|Farkas, Daniela; Thompson, A A Roger; Bhagwani, Aneel R et al. (2018) Toll-like Receptor 3 is a Therapeutic Target for Pulmonary Hypertension. Am J Respir Crit Care Med :|
|Goncharov, Dmitry A; Goncharova, Elena A; Tofovic, Stevan P et al. (2018) Metformin Therapy for Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction versus Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 198:681-684|
Showing the most recent 10 out of 182 publications